Express Pharma
Home  »  Latest Updates  »  DRL’s migraine drug ZEMBRACE SymTouch launched in US

DRL’s migraine drug ZEMBRACE SymTouch launched in US

Read Article

It is available in a box containing 4 autoinjectors

Promius Pharma, a subsidiary of Dr Reddy’s Laboratories (DRL), announced that ZEMBRACE SymTouch is now commercially available in the US. ZEMBRACE SymTouch is a prefilled, low-dose, ready-to-use, 2-step autoinjector containing 3 mg of sumatriptan, a selective 5-HT1B/ID receptor agonist. It being a subcutaneous injection, may lead to rapid relief of migraine.

“ZEMBRACE SymTouch is a welcome addition to the toolkit for acute treatment of migraine,” said Roger Cady, Associate Executive Chairman of the National Headache Foundation. “This 3-mg, easy to-use subcutaneous injection of sumatriptan may be desired by many migraine patients who need a medication that can rapidly treat migraine attacks. Also, the 3-mg dose allows for up to 4 doses of ZEMBRACE SymTouch in a 24-hour period, thus allowing dosing flexibility for patients.”

ZEMBRACE SymTouch is available as a box of 4 autoinjectors.

Comments are closed.

 Introducing Smart Autoinjector: Changing the paradigm of usability, cost & size
Know More?
Want to know more about "Omic's" and it's relevance?
Register Now